ConductScience.org, home
Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)
API referenceFor AI assistants

Trial · NCT03615326

Participant flow20

How many started, completed or left each group, period by period.

1 to 20 of 20

Download this page as JSON
PeriodMilestoneGroupParticipantsUnits counted
Overall StudySTARTEDGlobal Pembrolizumab + Standard of Care First Course350
Overall StudySTARTEDGlobal Standard of Care348
Overall StudySTARTEDJapan Pembrolizumab + Trastuzumab + S-1 Plus Oxaliplatin20
Overall StudySTARTEDJapan Trastuzumab + S-1 Plus Oxaliplatin20
Overall StudyTreatedGlobal Pembrolizumab + Standard of Care First Course350
Overall StudyTreatedGlobal Standard of Care346
Overall StudyTreatedJapan Pembrolizumab + Trastuzumab + S-1 Plus Oxaliplatin20
Overall StudyTreatedJapan Trastuzumab + S-1 Plus Oxaliplatin20
Overall StudyReceived Second Course of PembrolizumabGlobal Pembrolizumab + Standard of Care First Course11
Overall StudyReceived Second Course of PembrolizumabGlobal Standard of Care0
Overall StudyReceived Second Course of PembrolizumabJapan Pembrolizumab + Trastuzumab + S-1 Plus Oxaliplatin0
Overall StudyReceived Second Course of PembrolizumabJapan Trastuzumab + S-1 Plus Oxaliplatin0
Overall StudyCOMPLETEDGlobal Pembrolizumab + Standard of Care First Course0
Overall StudyCOMPLETEDGlobal Standard of Care0
Overall StudyCOMPLETEDJapan Pembrolizumab + Trastuzumab + S-1 Plus Oxaliplatin0
Overall StudyCOMPLETEDJapan Trastuzumab + S-1 Plus Oxaliplatin0
Overall StudyNOT COMPLETEDGlobal Pembrolizumab + Standard of Care First Course350
Overall StudyNOT COMPLETEDGlobal Standard of Care348
Overall StudyNOT COMPLETEDJapan Pembrolizumab + Trastuzumab + S-1 Plus Oxaliplatin20
Overall StudyNOT COMPLETEDJapan Trastuzumab + S-1 Plus Oxaliplatin20

Source ClinicalTrials.govtrials-2026-11-12-0.4.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNone stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03615326/flow

API referenceFor AI assistants